<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00622544</url>
  </required_header>
  <id_info>
    <org_study_id>0707M11722</org_study_id>
    <nct_id>NCT00622544</nct_id>
  </id_info>
  <brief_title>A Prospective Study of Microalbuminuria in Untreated Boys With Alport Syndrome</brief_title>
  <acronym>MA</acronym>
  <official_title>A Prospective Study of Microalbuminuria in Untreated Boys With Alport Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Minnesota</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Utah</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Minnesota</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of the Microalbuminuria in Untreated Boys with Alport Syndrome study is to gather
      information about critical clinical time points such as when patients with small amounts of
      protein (microalbuminuria) in their urine progress to larger amounts (overt proteinuria).
      Large amounts of protein in the urine is often an early sign of kidney disease.

      Information needs to be collected in boys who are not taking medications known as angiotensin
      converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB) in order to obtain
      accurate data about the length of time between the onset of microalbuminuria and the start of
      overt proteinuria. This new information will give physicians a better understanding of how to
      treat patients with Alport syndrome.

      The information we gather by conducting this study will aid in planning future clinical
      trials because the identification of time points in disease progression, such as
      microalbuminuria and overt proteinuria, could reduce the time necessary to show a clinical
      benefit of a new treatment option.

      The study has been approved by the University of Minnesota's Institutional Review Board.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Aims

        1. To determine the average ages of onset of microalbuminuria and overt proteinuria in
           untreated boys with Alport syndrome

        2. To determine the average duration of microalbuminuria before transition to overt
           proteinuria in untreated boys with Alport syndrome

      This study does not involve treatment and is anticipated to last 3-5 years.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2007</start_date>
  <completion_date type="Actual">July 2012</completion_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Subjects Developing Microalbuminuria During Study Period</measure>
    <time_frame>2007-2009</time_frame>
    <description>number of subjects developing microalbuminuria during study period</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Developing Proteinuria During the Study Period</measure>
    <time_frame>2007-2009</time_frame>
    <description>number of subjects developing proteinuria during the study period</description>
  </secondary_outcome>
  <enrollment type="Actual">44</enrollment>
  <condition>Alport Syndrome</condition>
  <condition>Kidney Disease</condition>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Each urine sample will be assayed for albumin, total protein and creatinine. The following
      definitions will be used:

        -  Microalbuminuria: urine albumin:creatinine ratio (ACR) &gt; 30 mcg/mg, on 3 consecutive
           measurements spaced one month apart

        -  Overt proteinuria: urine protein:creatinine ratio (UPC) &gt; 0.2 mg/mg, on 3 consecutive
           measurements spaced one month apart
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The study population is comprised of approximately 30 males ranging in age from 0 - 18 at
        the time of enrollment.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of Alport syndrome, confirmed by skin biopsy, kidney biopsy, or molecular
             genetic analysis

          -  Diagnosis of Alport syndrome, based on presence of hematuria and confirmed diagnosis
             of Alport syndrome in a first-degree relative

          -  Male gender

          -  Absence of overt proteinuria, defined as urine protein:creatinine ratio less than 0.2
             mg/mg

          -  Subject is not currently receiving treatment with an angiotensin converting enzyme
             inhibitor (ACEI) or angiotensin receptor blocker (ARB)

        Exclusion Criteria:

          -  Female gender

          -  Presence of overt proteinuria

          -  Current treatment with ACEI or ARB

          -  End-stage kidney disease (on dialysis or kidney transplant recipient)
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clifford E Kashtan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Minnesota</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://astor.ahc.umn.edu/</url>
    <description>Click here for more information about the Prospective Study of Microalbuminuria in Untreated Boys with Alport Syndrome (Alport Syndrome Treatments and Outcomes Registry)</description>
  </link>
  <verification_date>September 2017</verification_date>
  <study_first_submitted>February 13, 2008</study_first_submitted>
  <study_first_submitted_qc>February 22, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 25, 2008</study_first_posted>
  <results_first_submitted>May 2, 2017</results_first_submitted>
  <results_first_submitted_qc>September 22, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">July 20, 2018</results_first_posted>
  <last_update_submitted>September 22, 2017</last_update_submitted>
  <last_update_submitted_qc>September 22, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 20, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Microalbuminuria</keyword>
  <keyword>Proteinuria</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Nephritis, Hereditary</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Observational Study: no Arms - One Group</title>
          <description>Observational study of urine albumin and protein excretion in untreated boys with X-linked Alport syndrome</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="44"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="35">35</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Observational Study: no Arms - One Group</title>
          <description>Observational study of urine albumin and protein excretion in untreated boys with Alport syndrome</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="35"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9.9" spread="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects Developing Microalbuminuria During Study Period</title>
        <description>number of subjects developing microalbuminuria during study period</description>
        <time_frame>2007-2009</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Observational Study: no Arms - One Group</title>
            <description>Boys less than 18 years of age with a confirmed diagnosis of Alport syndrome</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Developing Microalbuminuria During Study Period</title>
          <description>number of subjects developing microalbuminuria during study period</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Developing Proteinuria During the Study Period</title>
        <description>number of subjects developing proteinuria during the study period</description>
        <time_frame>2007-2009</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Observational Study: no Arms - One Group</title>
            <description>Boys less than 18 years of age with a confirmed diagnosis of Alport syndrome</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Developing Proteinuria During the Study Period</title>
          <description>number of subjects developing proteinuria during the study period</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2007-2009</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Observational Study: no Arms - One Group</title>
          <description>Observational study of urine albumin and protein excretion in untreated boys with Alport syndrome</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clifford E. Kashtan</name_or_title>
      <organization>University of MN</organization>
      <phone>646 692 9309</phone>
      <email>cassi044@umn.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

